Astuokang Pharmaceutical Technology

Astuokang Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company's primary focus is on the development of next-generation treatments for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their lead programs include oral GLP-1 receptor agonists and multi-target agonists designed to improve patient compliance and therapeutic outcomes. Astuokang leverages its internal R&D capabilities to advance a pipeline of candidates through early-stage clinical trials in the Chinese market.